Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RA-DRUM
2023-510184-35-00Phase 4Authorised
- Sponsor
- Diakonhjemmet Sykehus AS, Medical University Of Vienna, Karolinska University Hospital, University Of Medicine And Pharmacy Carol Davila Bucharest, Humanitas Mirasole S.p.A.
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Diakonhjemmet Sykehus AS, Medical University Of Vienna, Karolinska University Hospital, University Of Medicine And Pharmacy Carol Davila Bucharest, Humanitas Mirasole S.p.A. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-510184-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510184-35-00.